Lung-specific sulfonium lipid nanoparticle formulation of dexamethasone suppresses endotoxin-induced lung inflammation - Takeaways - MDSpire

Lung-specific sulfonium lipid nanoparticle formulation of dexamethasone suppresses endotoxin-induced lung inflammation

  • By

  • Yuqin Men

  • Chunyan Wang

  • David O. Popoola

  • Zhi Cao

  • Weikun Tian

  • Robert N. Cooney

  • Qinghe Meng

  • Yamin Li

  • May 29, 2026

  • 0 min

Share

  • 1

    Dexamethasone is commonly used for treating acute lung injury (ALI) and acute respiratory distress syndrome (ARDS), but its efficacy and safety are debated.

  • 2

    The study developed a sulfonium lipid nanoparticle (sLNP) formulation, Dex/DOSEH, for targeted intravenous delivery of dexamethasone to the lungs.

  • 3

    In a murine model of LPS-induced ALI, Dex/DOSEH significantly reduced proinflammatory cytokines and immune cell infiltration compared to controls.

  • 4

    Dex/DOSEH preserved capillary-alveolar barrier integrity and attenuated histopathological lung injury, demonstrating robust anti-inflammatory effects.

  • 5

    The findings suggest that Dex/DOSEH represents a promising strategy for enhancing dexamethasone delivery and efficacy in treating ALI/ARDS.

Original Source(s)

Lung-specific sulfonium lipid nanoparticle formulation of dexamethasone suppresses endotoxin-induced lung inflammation

  • by Yuqin Men, Chunyan Wang, David O. Popoola, Zhi Cao, Weikun Tian, Robert N. Cooney, Qinghe Meng, Yamin Li

  • May 29, 2026

Related Content

Acute respiratory distress syndrome in patients with obesity

Predicting major organ complications in primary Sjögren’s disease using a machine learning ensemble strategy: a dual-center retrospective clinical study

Isoflurane for difficult sedation in critically ill children: a retrospective analysis in a mixed pediatric intensive care population